Indian Citalopram Exporters: Complete Supplier Ranking with Market Share — 736 Manufacturers (2026) — TransData Nexus

Q: Who is the largest citalopram buyer importing from India?

CIPLA MAROC (MOROCCO) is the largest citalopram importer from India with a 30.3% market share and import value of $77.2M.

Q: How many citalopram buyers import from India?

There are 736 active citalopram buyers importing from India, with a combined import market of $254.5M across 7,372 shipments according to Indian Customs (DGFT) records.

Q: What is the market share of top citalopram buyers from India?

The top 5 citalopram buyers — CIPLA MAROC, TORRENT PHARMA INC, MYLAN PHARMACEUTICALS INC, YUSEN LOGISTICS BENELUX BELGIUM, AUROLOGISTICS LLC (AUROBINDO PHARMA — together control 46.9% of total citalopram import value from India.

Suresh Sormare

Citalopram

India Pharmaceutical Trade Intelligence

$254.5M257 Suppliers101 CountriesHS 30049099

ExportsIndia → MOROCCO31.6%India → UNITED STATES28.8%

ImportsCANADA → India$5.3M UNITED STATES → India$24.9K

#1 Supplier: MEDISPRAY LABORATORIES #1 Buyer: CIPLA MAROC

Market Analysis: Top Importing Countries & Their Importers

1Morocco

Morocco emerges as the first largest importing country, achieving a total trade value of $80.4M through 71 shipments. This represents a market share of 31.6% of the total market activity, demonstrating their significant presence in the industry.

Top Importers: Morocco has a diverse importer base, with their top importers including:

• CIPLA MAROC - $77.2M (96.0% of country's total business)

Key Insight: Morocco demonstrates strong market positioning with an average shipment value of $1.1M, indicating premium pricing strategy compared to the market average of $34.5K.

Morocco is a key market for Citalopram imports, representing 31.6% of total trade value.

Primary Market

Secondary Market

2United States

United States emerges as the second largest importing country, achieving a total trade value of $73.4M through 758 shipments. This represents a market share of 28.8% of the total market activity, demonstrating their significant presence in the industry.

Buyer Segment Analysis

TransData Nexus Citalopram buyer market intelligence

1Buyer Segment Analysis

The importation of Citalopram from India involves various buyer segments, each with distinct purchasing behaviors and order patterns.

Distributors: Entities like Yusen Logistics Benelux Belgium and Aurobindo Pharma's U.S. subsidiary, AuroLogistics LLC, function as intermediaries, procuring large quantities of Citalopram for redistribution to pharmacies, hospitals, and other healthcare providers. Their bulk purchasing leverages economies of scale, ensuring consistent supply chains.

Contract Manufacturers: Companies such as Mylan Pharmaceuticals Inc. and Torrent Pharma Inc. import Citalopram as an active pharmaceutical ingredient (API) for formulation into finished dosage forms. Their procurement is characterized by large, periodic orders aligned with production schedules and market demand forecasts.

Re-exporters: Firms like Cipla Maroc in Morocco import Citalopram for domestic distribution and potential re-export to neighboring regions. Their purchasing patterns are influenced by both local demand and regional market opportunities, often involving substantial orders to maintain inventory for multiple markets.

Government Procurement: While not explicitly listed among the top buyers, government agencies and international organizations often engage in tender-based purchasing to supply public healthcare systems. Their procurement processes are typically characterized by large-volume orders awarded through competitive bidding, ensuring cost-effectiveness and broad access.

TransData Nexus Research · Government and regulatory sourcesMar 2026

Country-Specific Import Regulations

TransData Nexus Citalopram buyer market intelligence

1Country-Specific Import Regulations

Morocco:

1. Drug Regulatory Authority: Ministry of Health, Directorate of Medicines and Pharmacy.

2. Import Registration Process: Importers must obtain a marketing authorization (AMM) by submitting a dossier that includes product quality, safety, and efficacy data.

3. Estimated Timeline for Registration: Approximately 12 to 18 months, depending on dossier completeness and regulatory workload.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically exempt from import duties to facilitate access to essential medicines.

United States:

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process: Importers must ensure that the drug is FDA-approved and comply with labeling requirements.

3. Estimated Timeline for Registration: Varies; FDA approval processes can range from several months to over a year, depending on the application type and review process.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products are generally duty-free under this HS code.

Belgium:

1. Drug Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).

2. Import Registration Process: Requires a marketing authorization obtained by submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy.

3. Estimated Timeline for Registration: Approximately 12 to 24 months, subject to dossier completeness and regulatory review periods.

4. Import Tariff/Duty for HS 30049099: As part of the European Union, Belgium applies a common external tariff; however, pharmaceutical products are typically exempt from import duties.

Demand Drivers & Market Opportunity

TransData Nexus Citalopram buyer market intelligence

1Demand Drivers & Market Opportunity

The demand for Citalopram, a selective serotonin reuptake inhibitor (SSRI) used primarily to treat depression, is influenced by several factors:

1. Disease Prevalence: Depression is a leading cause of disability worldwide. According to the World Health Organization (WHO), over 280 million people globally suffer from depression as of 2025.

2. Government Healthcare Programs: Many countries have integrated mental health services into their primary healthcare systems, increasing the accessibility of antidepressants like Citalopram.

3. Universal Health Coverage Expansion: The global push towards universal health coverage has led to increased availability and affordability of essential medicines, including antidepressants.

4. WHO Essential Medicines List Procurement: Citalopram's inclusion in the WHO Model List of Essential Medicines underscores its importance, prompting countries to prioritize its procurement.

5. Tender-Based Purchasing: Government and international organizations often procure medicines through competitive tenders, ensuring cost-effectiveness and broad access.

Our data indicates that between 2022 and 2026, 736 buyers across 101 countries imported Citalopram from India, reflecting its widespread demand and the global recognition of its therapeutic value.

TransData Nexus Research · Government and regulatory sourcesMar 2026

Common Questions — Citalopram Buyers & Importers

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

QWho is the largest citalopram buyer importing from India?

Based on import volume and value, CIPLA MAROC (MOROCCO) leads with $77.2M in imports and a 30.3% market share — the highest of any single citalopram importer. TORRENT PHARMA INC (UNITED STATES) and MYLAN PHARMACEUTICALS INC (UNITED STATES) are the next largest buyers.

QHow many companies buy citalopram from India?

There are 736 active citalopram buyers importing from India, with a combined market of $254.5M across 7,372 shipments to 101 countries. The top 5 buyers hold 46.9% of total import value, while the remaining 731 buyers handle the other 53.1%.

QWhich countries import the most citalopram from India?

The top importing countries for citalopram from India are Morocco (31.6%), United States (28.8%), Belgium (4.7%), Brazil (4.2%), Canada (4.0%). These markets represent the largest demand centres for Indian pharmaceutical exports of citalopram, with buyers ranging from government procurement agencies to private pharmaceutical distributors.